Economic Costs of Rotavirus Gastroenteritis and Cost‐Effectiveness of Vaccination in Developing Countries

Rheingans, Richard; Antil, Lynn; Dreibelbis, Robert; Podewils, Laura Jean; Bresee, Joseph S.; Parashar, Umesh D.

doi:10.1086/605026

Cited by 104 publications

(90 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Richard Rheingans and colleagues estimated $196 million in annual treatment costs averted because of the introduction of rotavirus vaccine in low-and middle-income countries (converted to 2009 US dollars). 33 Similar assumptions about rates of vaccination can be found in year 2014 of our analysis, where we projected annual treatment savings from rotavirus vaccine of $212 million in 2009 US dollars.…”

Section: Discussionmentioning

confidence: 74%

Estimated Economic Benefits During The ‘Decade Of Vaccines’ Include Treatment Savings, Gains In Labor Productivity

et al. 2011

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 74%

Estimated Economic Benefits During The ‘Decade Of Vaccines’ Include Treatment Savings, Gains In Labor Productivity

et al. 2011

View full text Add to dashboard Cite

“…The significant morbidity and mortality related to rotavirus gastroenteritis (RGE) results in a tremendous economic burden on health care systems worldwide and greatly impacts families of children infected with the virus (Mast et al 2009, Rheingans et al 2009). International health agencies have determined that the development of rotavirus vaccines is the best means of preventing morbidity and mortality due to rotavirus infection (Bressee et al 2005, Guarino et al 2008 (Gentsch et al 1996, Santos & Hoshino 2005, Matthijnssens et al 2008.…”

mentioning

confidence: 99%

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil

Khoury

Mast

Ciarlet³

et al. 2011

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

RotaTeq® (Merck & Company, Inc, Whitehouse Station, NJ, USA) is an oral pentavalent rotavirus vaccine (RV5) that has shown high and consistent efficacy in preventing rotavirus gastroenteritis (RGE) in randomised clinical trials previously conducted in industrialised countries with high medical care resources. To date, the efficacy and effectiveness data for RV5 are available in some Latin American countries, but not Brazil. In this analysis, we projected the effectiveness of RV5 in terms of the percentage reduction in RGE-related hospitalisations among children less than five years of age in four regions of Brazil, using a previously validated mathematical model. The model inputs included hospital-based rotavirus surveillance data from Goiânia, Porto Alegre, Salvador and São Paulo from 2005-2006, which provided the proportions of rotavirus attributable to serotypes G1, G2, G3, G4 and G9, and published rotavirus serotype-specific efficacy from the Rotavirus Efficacy and Safety Trial. The model projected an overall percentage reduction of 93% in RGE-related hospitalisations, with an estimated annual reduction in RGE-related hospitalisations between 42,991-77,383 in the four combined regions of Brazil. These results suggest that RV5 could substantially prevent RGE-related hospitalisations in Brazil

show abstract

“…2008, the burden of diarrhea due to rotavirus was estimated 453000 deaths and 27 million medical visits and majority of these took place in low and middle income countries. 1,2 In low income countries the median age at the primary rotavirus infection ranges from 6 to 12 months whereas in high income countries, the first episode may be delayed for 2 to 3 y. 2,3,4 induces partial immunity and subsequent (secondary and tertiary) infections are presented clinically mild or asymptomatic.…”

Section: Introductionmentioning

confidence: 99%

The cost effectiveness of rotavirus vaccination in Iran

Jarrahi

Zahraei

Sadigh

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death among young children. Effective vaccines have recently been approved and successful vaccination program implemented. The aim of this study was to evaluate the cost effectiveness of mass rotavirus vaccination program in Iran. We developed a Markov model that reflects key features of rotavirus natural history. Parameters of the model were assessed by field study or developed through literature search and published data. We applied the model to the 2009 Iranian birth cohort and evaluated the costeffectiveness of including the rotavirus vaccine (Rotarix®) into Iranian expanded immunization program (EPI). With an estimated hospitalization rate of 0.05 and outpatient rate of 0.23 cases per person-year, vaccinating cohort of 1231735 infants in Iran with 2 doses of (Rotarix®), would prevent 32092 hospitalizations, 158750 outpatient visits, and 1591 deaths during 5 y of follow-up. Under base-case assumption of $10 cost per course of vaccine, the vaccination would incur an extra cost of $1,019,192 from health care perspective and would avert 54680 DALYs. From societal perspective, there would be $15,192,568 saving for the society with the same averted DALYs. The incremental cost effectiveness ratio showed a cost of $19 US dollars per averted DALY from health care perspective and a saving of $278 US dollars for each averted DALY from societal perspective. Introducing rotavirus vaccine into EPI program would be highly cost-effective public health intervention in Iran.

show abstract

Economic Costs of Rotavirus Gastroenteritis and Cost‐Effectiveness of Vaccination in Developing Countries

Abstract: Vaccination is a cost-effective strategy to reduce the health and economic burden of rotavirus. The cost-effectiveness of vaccination depends mostly on vaccine price and reaching children at highest risk of mortality.

Cited by 104 publications

References 54 publications

Estimated Economic Benefits During The ‘Decade Of Vaccines’ Include Treatment Savings, Gains In Labor Productivity

Estimated Economic Benefits During The ‘Decade Of Vaccines’ Include Treatment Savings, Gains In Labor Productivity

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil

The cost effectiveness of rotavirus vaccination in Iran

Contact Info

Product

Resources

About